var data={"title":"Acyclovir (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Acyclovir (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/386630?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=acyclovir-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Acyclovir (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=acyclovir-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Acyclovir (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7808291\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zovirax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7808292\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Zovirax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7912017\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiviral Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7901185\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Herpes simplex virus (HSV), genital infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunocompetent:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Initial episode, severe: 5 to 10 mg/kg/dose every 8 hours for 2 to 7 days, follow with oral therapy to complete at least 10 days of therapy (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial episode: 200 mg 5 times daily for 7 to 10 days <b>or</b> 400 mg 3 times daily for 7 to 10 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Recurrence: 400 mg 3 times daily for 5 days <b>or</b> 800 mg twice daily for 5 days <b>or</b> 800 mg 3 times daily for 2 days; <b>Note:</b> Initiate within 1 day of lesion onset or during the preceding prodrome (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Chronic suppression: 400 mg twice daily for up to 12 months (followed by re-evaluation); <b>Note: </b>Safety and efficacy have been documented in patients receiving daily therapy with acyclovir for up to 6 years (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HIV-infected patients: See off-label uses below.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>HSV encephalitis:</b> IV: Independent of HIV status: 10 mg/kg/dose every 8 hours for 14 to 21 days (IDSA [Tunkel 2008])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>HSV, mucocutaneous treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunocompromised:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 5 to 10 mg/kg/dose every 8 hours for 7 days (Leflore 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (off-label use): 400 mg 5 times daily for 7 days (Leflore 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HIV-infected patients: See off-label uses below.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Herpes zoster (shingles) (treatment):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunocompromised:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 10 mg/kg/dose every 8 hours for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 800 mg 5 times daily for 7 to 10 day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HIV-infected patients (HHS [OI adult 2017]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: <i>Extensive cutaneous lesions or visceral involvement:</i> 10 to 15 mg/kg/dose every 8 hours until clinical improvement; switch to oral famciclovir or valacyclovir (preferred) or acyclovir (alternative) to complete a 10 to 14 day course when formation of new lesions has ceased and signs/symptoms of visceral infection are improving</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (off-label use): <i>Acute localized infection (as an alternative to valacyclovir or famciclovir):</i> 800 mg 5 times daily for 7 to 10 days; consider longer duration if lesions resolve slowly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Bell palsy (new onset) (off-label use): </b>Oral: 400 mg 5 times daily for 10 days in combination with corticosteroids. <b>Note:</b> Benefit of the addition of antivirals to corticosteroid therapy has not been established and antivirals provide only marginal benefit over corticosteroid therapy alone (Gronseth 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Cytomegalovirus (CMV) infection (prophylaxis in low-risk allogeneic HSCT recipients) (off-label use; alternate therapy): Note:</b> Begin at engraftment and continue to day 100; requires close monitoring for CMV reactivation (due to weak activity); not for use in patients at high risk for CMV disease (Tomblyn 2009): Adults &ge;40 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 500 mg/<b>m<sup>2</sup></b>/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 800 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Herpes simplex virus (HSV), genital infection in </b>\n      <b>HIV-infected patients (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial or recurrent episodes: 400 mg 3 times daily for 5 to 10 days (CDC [Workowski 2015]; HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic suppressive therapy: 400 mg twice daily; continue indefinitely regardless of CD4 count in patients with severe recurrences of genital herpes or in patients who want to minimize frequency of recurrences (HHS [OI adult 2017]) <b>or</b> 400 to 800 mg 2 to 3 times daily (CDC [Workowski 2015]). In patients beginning antiretroviral therapy and concomitant acyclovir, a reduction in the incidence of HSV-2 genital ulcers is most evident after the first 3 months of ART initiation (Fife 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>HSV, mucocutaneous infection in HIV-infected patients (off-label use): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 5 mg/kg/dose every 8 hours; may switch to oral acyclovir after lesions begin to heal (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: After initial IV therapy, may switch to 400 mg 3 times daily; continue until lesions are completely healed (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>HSV, orolabial (cold sores) infection in immunocompetent patients (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment: (episodic/recurrent): 200 to 400 mg 5 times daily for 5 days (Cernik 2008; Leflore 2000; Spruance 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic suppression: 400 mg 2 times daily (has been clinically evaluated for up to 1 year) (Cernik 2008; Rooney 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>HSV, </b>\n      <b>orolabial (cold sores) infection in </b>\n      <b>HIV-infected patients (off-label use):</b> Treatment: Oral: 400 mg 3 times daily for 5 to 10 days (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>HSV reactivation </b>\n      <b>(prevention in seropositive immunocompromised patients) (off-label use): </b>Adults &ge;40 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hematopoietic stem cell transplant (HSCT) recipients (prevention of early HSV reactivation)<b>: </b></i>\n      <b>Note:</b> Start at the beginning of conditioning therapy and continue until engraftment or until mucositis resolves (~30 days) (Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 250 mg/<b>m<sup>2</sup></b> every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 400 to 800 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HSCT recipients (prevention of late HSV reactivation)<b>: </b></i>Oral: 800 mg twice daily; continue therapy for 1 year after HSCT (Tomblyn 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Undergoing AML induction or reinduction therapy: </i>Oral: 400 mg twice daily; continue during active therapy and throughout periods of neutropenia (Bergmann 1995; Freifeld 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Varicella (chickenpox), treatment:</b> Typically, valacyclovir is used for this indication since it may be administered less frequently. Begin treatment within the first 24 hours of rash onset:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: HIV-infected patients (off-label use): Severe or complicated cases: 10 to 15 mg/kg/dose every 8 hours for 7 to 10 days; may switch to oral famciclovir or valacyclovir (preferred) or acyclovir (alternative) after defervescence if no evidence of visceral involvement (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunocompetent (&gt;40 kg): 800 mg 4 times daily for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-infected patients (off-label use): <i>Uncomplicated cases (as an alternative to valacyclovir or famciclovir):</i> 800 mg 5 times daily for 5 to 7 days (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Varicella-zoster virus (VZV) acute retinal necrosis (ARN) in HIV-infected patients (off-label use):</b> IV: 10 to 15 mg/kg/dose every 8 hours for 10 to 14 days, followed by valacyclovir for 6 weeks plus intravitreal ganciclovir twice weekly for 1 to 2 doses (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>VZV reactivation (prevention in HSCT recipients) (off-label use):</b> Adults &ge; 40 kg: Oral: 800 mg twice daily; continue therapy for 1 year after HSCT (Tomblyn 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7901184\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=acyclovir-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Acyclovir (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Obese patients should be dosed using ideal body weight. Parenteral IV doses &gt;15 mg/kg/dose or 500 mg/m<sup>2</sup> may be associated with an increased risk of nephrotoxicity; close monitoring of renal function is recommended (Rao 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CMV prophylaxis:</b> Low-risk allogeneic hematopoietic stem cell transplant (HSCT) in seropositive recipient. <b>Note:</b> Begin at engraftment and continue to day 100; requires close monitoring for CMV reactivation (due to weak activity); not for use in patients at high risk for CMV disease (Tomblyn 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents &lt;40 kg: 600 mg/m<sup>2</sup>/dose 4 times daily; maximum dose: 800 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &ge;40 kg: 800 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Infants, Children, and Adolescents: 500 mg/m<sup>2</sup>/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Herpes zoster, acute retinal necrosis, treatment (HIV-exposed/-positive):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial treatment: IV: <b>Note:</b> Follow up IV therapy with oral acyclovir or valacyclovir maintenance therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 10 to 15 mg/kg/dose every 8 hours for 10 to 14 days (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: 10 to 15 mg/kg/dose <b>or</b> 500 mg/<b>m</b><b><sup>2</sup></b>/dose every 8 hours for 10 to 14 days (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: 10 to 15 mg/kg/dose every 8 hours for 10 to 14 days (DHHS [adult] 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance treatment; begin after 10 to 14 day course of IV acyclovir: Oral: Infants and Children: 20 mg/kg/dose 4 times daily for 4 to 6 weeks (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Herpes zoster (shingles), treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immunocompetent host:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ambulatory therapy: Oral: Children &ge;12 years and Adolescents: 800 mg every 4 hours (5 doses per day) for 5 to 7 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hospitalized patient: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: 10 mg/kg/dose every 8 hours for 7 to 10 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: 500 mg/<b>m</b><b><sup>2</sup></b>/dose every 8 hours for 7 to 10 days; some experts recommend 10 mg/kg/dose every 8 hours (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immunocompromised host (non-HIV-exposed/-positive):</i> IV: Infants, Children, and Adolescents: 10 mg/kg/dose every 8 hours for 7 to 10 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-exposed/-positive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild, uncomplicated disease and no or moderate immune suppression: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: 20 mg/kg/dose 4 times daily for 7 to 10 days; maximum dose: 800 mg/dose; consider longer course if resolution of lesions is slow (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: 800 mg 5 times daily for 7 to 10 days, longer if lesions resolve slowly (DHHS [adult] 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe immune suppression or complicated disease; trigeminal nerve involvement, extensive multidermatomal zoster or extensive cutaneous lesions or visceral involvement: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: 10 mg/kg/dose every 8 hours until resolution of cutaneous lesions and visceral disease clearly begins, then convert to oral therapy to complete a 10- to 14-day total course of therapy (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children: 10 mg/kg/dose <b>or</b> 500 mg/<b>m</b><b><sup>2</sup></b>/dose every 8 hours until resolution of cutaneous lesions and visceral disease clearly begins, then convert to oral therapy to complete a 10- to 14-day total course of therapy (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: 10 to 15 mg/kg/dose every 8 hours until clinical improvement is evident, then convert to oral therapy to complete a 10- to 14-day total course of therapy (DHHS [adult] 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HSV neonatal infection, treatment and suppressive therapy in very young infants (independent of HIV status):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment (disseminated, CNS, or skin, eye, or mouth disease): Infants 1 to 3 months: IV: 20 mg/kg/dose every 8 hours; treatment duration: For cutaneous and mucous membrane infections (skin, eye, or mouth): 14 days; for CNS or disseminated infection: 21 days (AAP [Kimberlin 2013]; Bradley 2015; CDC [Workowski 2015]; DHHS [pediatric] 2013; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic suppressive therapy following any neonatal HSV infection:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AAP Recommendation (low dose, 6-month-course): Infants: Oral: 300 mg/<b>m</b><b><sup>2</sup></b>/dose every 8 hours for 6 months; begin after completion of a 14- to 21-day-course of IV therapy dependent upon type of infection (AAP [Kimberlin 2013]; Kimberlin 2011; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing (high dose, 2-year-course) in infants with disseminated or CNS infection (Tiffany 2005): Limited data available: Infants and Children &lt;3 years: Oral: Begin after completion of a 21-day course of IV therapy; dosing based on a prospective trial of 16 consecutive neonates (GA: Premature: n=4; term= 12; age at treatment: Neonate: n=14; PNA &gt;30 days: n=1) following disseminated or CNS infection; pharmacokinetic data were used to determine dosing regimen to maintain serum acyclovir concentration above target of 2 to 3 mcg/mL; treatment was continued for 2 years in 14 of 16 patients; results showed normal neurodevelopmental outcomes in 69% and normal motor development in 70%; no untoward effects were reported during the study duration.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial dosing: 400 mg twice daily; approximate dose: 1,200 to 1,600 mg/m<sup>2</sup>/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dosing: <b>Note</b>: Approximate doses for patients born at term:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants 1 to &lt;5 months: 400 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants 5 to &lt;9 months: 600 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children 9 to &lt;15 months: 800 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children 15 to 24 months: 1,000 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> In the trial, serum acyclovir concentrations were evaluated to assess adequacy of dosing to maintain serum concentrations above the target of 2 to 3 mcg/mL. Samples were collected 1 hour after a witnessed dose; if the acyclovir serum concentration approached or was below the target, the dose was increased to the next greater 200 mg increment. Maximum dose: 1,200 mg. Serum concentrations were evaluated every 3 months; in order to limit the phlebotomy losses, follow-up serum concentrations were not evaluated outside of routine monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HSV encephalitis, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children 3 months to &lt;12 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Non-HIV-exposed/-positive:</i> IV: 10 to 15 mg/kg/dose every 8 hours for 14 to 21 days. <b>Note:</b> Due to increased risk of neurotoxicity and nephrotoxicity, higher doses (20 mg/kg) are not recommended (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-exposed/-positive: </i>IV: 10 mg/kg/dose every 8 hours for 21 days; higher doses (up to 20 mg/kg) may be necessary (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents (independent of HIV status): IV: 10 mg/kg/dose every 8 hours for 14 to 21 days (<i>Red Book</i> [AAP 2015)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HSV genital infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">First infection, mild to moderate:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Non-HIV-exposed/-positive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &lt;12 years: Oral: 40 to 80 mg/kg/<b>day</b> divided in 3 to 4 doses per day for 5 to 10 days; maximum daily dose: 1,200 mg/<b>day</b> (Bradley 2015; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &ge;12 years: Oral: 200 mg every 4 hours while awake (5 times daily) <b>or</b> 400 mg 3 times daily for 7 to 10 days; treatment can be extended beyond 10 days if healing is not complete (CDC [Workowski 2015]; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-exposed/-positive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children: Oral: 20 mg/kg/dose 3 times daily for 7 to 10 days; maximum dose: 400 mg/dose (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Oral: 400 mg 3 times daily for 5 to 10 days (DHHS [adult] 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">First infection, severe (independent of HIV status): IV: Children and Adolescents &ge;12 years: 5 mg/kg/dose every 8 hours for 5 to 7 days <b>or</b> 5 to 10 mg/kg/dose every 8 hours for 2 to 7 days, followed with oral therapy to complete at least 10 days of therapy (CDC [Workowski 2015]; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Recurrent infection:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;12 years (independent of HIV status): Oral: 20 mg/kg/dose 3 times daily for 5 days; maximum dose: 400 mg/dose (Bradley 2015; DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &ge;12 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Non-HIV-exposed/-positive:</i> Oral: 200 mg every 4 hours while awake (5 times daily) for 5 days, <b>or</b> 400 mg 3 times daily for 5 days, <b>or</b> 800 mg twice daily for 5 days <b>or</b> 800 mg 3 times daily for 2 days (CDC [Workowski 2015]; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>HIV-exposed/-positive:</i> Adolescents: Oral: 400 mg 3 times daily for 5 to 14 days (DHHS [adult] 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suppression, chronic:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Non-HIV-exposed/-positive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &lt;12 years: Limited data available: Oral: 20 mg/kg/dose twice daily; maximum dose: 400 mg/dose (Bradley 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &ge;12 years: Oral: 400 mg twice daily; reassess therapy after 12 months (CDC [Workowski 2015]; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-exposed/-positive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: Oral: 20 mg/kg/dose twice daily; maximum dose: 800 mg/dose (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Oral: 400 mg twice daily (DHHS [adult] 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HSV gingivostomatitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Non-HIV-exposed/-positive:</i> Primary infection:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AAP recommendations: Children and Adolescents: Oral: 20 mg/kg/dose 4 times daily for 5 to 7 days; usual maximum dose: 200 mg/dose, others have reported higher (400 mg/dose) (Bradley 2015; Cernik, 2008; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Infants &ge;10 months, Children, and Adolescents: Oral: 15 mg/kg/dose five times daily for 7 days; maximum dose: 200 mg/dose (Amir 1997; Balfour 1999); dosing based on a placebo controlled trial in children 1 to 6 years of age (n=72, treatment group: n=31); results showed when treatment started within 72 hours of symptom onset a shorter duration of symptoms and viral shedding was observed (Amir 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-exposed/-positive</i> (DHHS [pediatric] 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild, symptomatic: Oral: Infants and Children: 20 mg/kg/dose 4 times daily for 7 to 10 days; maximum dose: 400 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate to severe, symptomatic: IV: Infants and Children: 5 to 10 mg/kg/dose every 8 hours; switch to oral therapy once lesions begin to regress</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HSV, herpes labialis (cold sore) (HIV-exposed/-positive):</b> Treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children: Oral: 20 mg/kg/dose 4 times daily for 5 days; maximum dose: 400 mg/dose (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents: Oral: 400 mg 3 times daily for 5 to 10 days (DHHS [adult] 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HSV, herpes labialis (cold sore) recurrent, chronic suppressive therapy:</b> Immunocompetent Children and Adolescents: Oral: 10 mg/kg/dose 3 times daily; maximum daily dose: 1,000 mg/<b>day</b>; reevaluate after 12 months (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HSV mucocutaneous infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immunocompetent host:</i> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment (Bradley 2015):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 5 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 20 mg/kg/dose 4 times daily for 5 to 7 days; maximum dose: 800 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Suppression, chronic: Limited data available; no pediatric data; some experts recommend oral 20 mg/kg/dose 2 to 3 times daily for 6 to 12 months, then reevaluate need; maximum dose: 400 mg/dose (Bradley 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immunocompromised host:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children: 10 mg/kg/dose every 8 hours for 7 to 14 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents: 5 to 10 mg/kg/dose every 8 hours; change to oral therapy (ie, 400 mg 3 times daily) after lesions begin to regress (DHHS [adult] 2017; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: Children &ge;2 years and Adolescents: 1,000 mg/<b>day</b> in 3 to 5 divided doses for 7 to 14 days; some suggest the maximum daily dose should not exceed 80 mg/kg/<b>day</b> (<i>Red Book</i> 2009; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Suppression, chronic (cutaneous, ocular) episodes:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children (HIV-exposed/-positive): Oral: 20 mg/kg/dose twice daily; maximum dose: 800 mg/dose; reassess after 12 months (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 12 years of age (non-HIV-exposed/-positive): Prevention of ocular episodes: Oral: 400 mg twice daily; reassess at 12 months (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents (independent of HIV status): Oral: 400 mg twice daily; reassess at 12 months (DHHS [adult] 2017; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HSV progressive or disseminated infection, treatment (immunocompromised host):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HIV-exposed/-positive: Infants, Children, and Adolescents: IV: 10 mg/kg/dose every 8 hours for 7 to 14 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HIV-exposed/-positive: Infants, Children, and Adolescents: IV: 10 mg/kg/dose every 8 hours for 21 days; higher doses (up to 20 mg/kg/dose) may be used in children &lt;12 years of age (DHHS [pediatric] 2013; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HSV, acute retinal necrosis, treatment (HIV-exposed/-positive):</b> Children (DHHS [pediatric] 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial treatment: IV: 10 to 15 mg/kg/dose every 8 hours for 10 to 14 days. <b>Note:</b> Follow up IV therapy with oral acyclovir or valacyclovir maintenance therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance treatment: Begin after 10 to 14 day course of IV acyclovir: Oral: 20 mg/kg/dose 4 times daily for 4 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HSV prophylaxis; immunocompromised hosts, seropositive:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hematopoietic stem cell transplant (HSCT) in seropositive recipient</i> (Tomblyn, 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prevention of early reactivation: <b>Note:</b> Begin at conditioning and continue until engraftment or resolution of mucositis; whichever is longer (~30 days post-HSCT)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, Children, and Adolescents &lt;40 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 250 mg/<b>m</b><b><sup>2</sup></b>/dose every 8 hours <b>or</b> 125 mg/<b>m</b><b><sup>2</sup></b>/dose every 6 hours; maximum daily dose: 80 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 60 to 90 mg/kg/<b>day</b> in 2 to 3 divided doses; maximum dose: 800 mg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &ge;40 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 250 mg/<b>m</b><b><sup>2</sup></b>/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 400 to 800 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prevention of late reactivation: <b>Note:</b> Treatment during first year after HSCT.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, Children, and Adolescents &lt;40 kg: Oral: 60 to 90 mg/kg/<b>day</b> in 2 to 3 divided doses; maximum daily dose: 800 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &ge;40 kg: Oral: 800 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Other immunocompromised hosts who are HSV seropositive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Infants, Children, and Adolescents: 5 mg/kg/dose every 8 hours during period of risk (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Children &ge;2 years and Adolescents: 200 mg every 4 hours while awake (5 doses daily) <b>or</b> 200 mg every 8 hours; administer during periods of risk (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Varicella (chickenpox) or Herpes zoster (shingles), prophylaxis</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hematopoietic stem cell transplant (HSCT):</i> Prophylaxis of disease reactivation: <b>Note:</b> Continue therapy for 1 year after HSCT (Tomblyn 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents &lt;40 kg: Oral: 60 to 80 mg/kg/day in 2 to 3 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &ge;40 kg: Oral: 800 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-exposed/-positive:</i> Limited data available: <b>Note:</b> Consider use if &gt;96 hours postexposure or if VZV-immune globulin is not available; begin therapy 7 to 10 days after exposure; some experts begin therapy at first appearance of rash (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: Oral: 20 mg/kg/dose 4 times daily for 7 days; maximum dose: 800 mg/dose (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Oral: 800 mg 5 times daily for 5 to 7 days (DHHS [adult] 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Other immunocompromised hosts:</i> Infants, Children, and Adolescents: Oral: 20 mg/kg/dose 4 times daily for 7 days; maximum dose: 800 mg/dose. <b>Note:</b> Consider use if VZV-immune globulin or IVIG is not available; begin therapy 7 to 10 days after exposure (<i>Red Book</i> [AAP] 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Varicella (chickenpox), treatment:</b> Begin treatment within the first 24 hours of rash onset:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immunocompetent host:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ambulatory therapy: Oral: Children &ge;2 years and Adolescents: 20 mg/kg/dose 4 times daily for 5 days; maximum daily dose: 3,200 mg/<b>day</b> (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hospitalized patient: IV: Infants, Children, and Adolescents: 10 mg/kg/dose <b>or</b> 500 mg/<b>m</b><b><sup>2</sup></b>/dose every 8 hours for 7 to 14 days (Bradley 2015; <i>Red Book</i> [AAP 2015]); some experts recommend 15 to 20 mg/kg/dose for severe disseminated or CNS infection (Bradley 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immunocompromised host (non-HIV-exposed/-positive):</i> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 10 mg/kg/dose every 8 hours for 7 to 10 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: 500 mg/<b>m</b><b><sup>2</sup></b>/dose every 8 hours for 7 to 10 days; some experts recommend 10 mg/kg/dose every 8 hours (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-exposed/-positive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild, uncomplicated disease and no or moderate immune suppression: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: 20 mg/kg/dose 4 times daily for 7 to 10 days and until no new lesions for 48 hours; maximum dose: 800 mg/dose (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: 800 mg 5 times daily for 5 to 7 days (DHHS [adult] 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe, complicated disease or severe immune suppression: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: 10 mg/kg/dose every 8 hours for 7 to 10 days and until no new lesions for 48 hours (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children: 10 mg/kg/dose <b>or</b> 500 mg/<b>m</b><b><sup>2</sup></b>/dose every 8 hours for 7 to 10 days or until no new lesions for 48 hours (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: 10 to 15 mg/kg/dose every 8 hours for 7 to 10 days; may convert to oral therapy after defervescence and if no evidence of visceral involvement is evident (DHHS [adult] 2017)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7901186\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7901187\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Monitor closely for neurotoxicity (Chowdhury 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;25 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 25 mL/minute/1.73 m<sup>2</sup>: If the usual recommended dose is 800 mg 5 times daily: Administer 800 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If the usual recommended dose is 200 mg 5 times daily or 400 mg every 12 hours: Administer 200 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If the usual recommended dose is 800 mg 5 times daily: Administer 200 mg every 12 hours (IDSA [Gupta 2005])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent hemodialysis (IHD): Dialyzable (60% reduction following a 6-hour session):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Dosing dependent on the assumption of 3 times weekly, complete IHD sessions. Administer after hemodialysis on dialysis days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If the usual recommended dose is 200 mg 5 times daily or 400 mg every 12 hours: Administer 200 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If the usual recommended dose is 800 mg 5 times daily: Administer a loading dose of 400 mg and a maintenance dose of 200 mg twice daily plus a single 400 mg dose after each dialysis (Almond 1995). <b>Note:</b> Dose based on pharmacokinetic data and computer modeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous ambulatory peritoneal dialysis (CAPD): 600 to 800 mg daily (Stathoulopoulou 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>If the usual recommended dose is 10 mg/kg/dose every 8 hours:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 25 to 50 mL/minute/1.73 m<sup>2</sup>: 10 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to &lt;25 mL/minute/1.73 m<sup>2</sup>: 10 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>: 5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>If the usual recommended dose is 5 mg/kg/dose every 8 hours:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 25 to 50 mL/minute/1.73 m<sup>2</sup>: 5 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to &lt;25 mL/minute/1.73 m<sup>2</sup>: 5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>: 2.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent hemodialysis (IHD): Dialyzable (60% reduction following a 6-hour session): 2.5 to 5 mg/kg/dose every 24 hours (Heintz 2009). <b>Note:</b> Use higher end of dosing range for viral meningoencephalitis and varicella-zoster infections. Dosing dependent on the assumption of 3 times weekly, complete IHD sessions. Administer after hemodialysis on dialysis days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis (PD): 2.5 to 5 mg/kg/dose every 24 hours; no supplemental dose needed (Aronoff 2007). <b>Note:</b> Use higher end of dosing range for viral meningoencephalitis and varicella-zoster infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVH: 5 to 10 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CVVHD/CVVHDF: 5 to 10 mg/kg/dose every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> The higher end of dosage range is recommended for viral meningoencephalitis and varicella-zoster virus infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671282\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Oral, IV: There are no dosage adjustments provided in the manufacturer's labeling; use caution in patients with severe impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20330460\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">IV: In obese patients, acyclovir IV has been dosed using ideal body weight (IBW) to avoid overdosing and subsequent toxicity. However, in a pharmacokinetic study using a single acyclovir IV dose, morbidly obese patients (BMI &ge; 40 kg/m<sup>2</sup>) dosed using IBW had lower systemic exposures compared to normal weight subjects dosed using actual body weight (exposure based on AUC, C<sub>max</sub>, and T &gt; IC<sub>50 </sub>[time the drug concentration remains above the 50% inhibitory concentration]) (Turner 2016). Therefore, to avoid potentially underdosing obese patients who are severely ill (eg, HSV encephalitis), some clinicians use adjusted body weight (AjBW) to determine the IV dose (AjBW=IBW + [0.4 x (actual body weight-IBW)]) (Wong 2017), although this approach has not been evaluated in clinical studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7901193\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zovirax: 200 mg [contains fd&amp;c blue #2 (indigotine), parabens]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (10 mL, 20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea); 1000 mg (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zovirax: 200 mg/5 mL (473 mL [DSC]) [contains methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zovirax: 200 mg/5 mL (473 mL) [contains methylparaben, propylparaben; banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg/5 mL (473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zovirax: 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zovirax: 800 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 mg, 800 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7908323\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7808318\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Avoid rapid infusion; infuse over 1 hour to prevent renal damage; maintain adequate hydration of patient; check for phlebitis and rotate infusion sites. Do not administer IM or SubQ. Acyclovir IV is an irritant (depending on concentration); avoid extravasation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7908324\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Herpes zoster (shingles):</i> Acute treatment of herpes zoster (shingles).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Herpes simplex virus (HSV), genital:</i> Treatment of initial episodes and the management of recurrent episodes of genital herpes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Varicella (chickenpox): </i>Treatment of varicella (chickenpox).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Injection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Herpes simplex virus (HSV), mucocutaneous infection in immunocompromised patients:</i> Treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Herpes simplex virus (HSV), genital infection (severe):</i> Treatment of severe initial clinical episodes of genital herpes in immunocompetent patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Herpes simplex encephalitis:</i> Treatment of herpes simplex encephalitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Herpes simplex virus (HSV), neonatal:</i> Treatment of neonatal herpes infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Herpes zoster (shingles) in immunocompromised patients:</i> Treatment of herpes zoster (shingles) in immunocompromised patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475020\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bell palsy (new onset); Cytomegalovirus (CMV) infection (prophylaxis in low-risk allogeneic HSCT recipients); Herpes simplex virus (HSV), genital infection in HIV-infected patients (adolescents and adults); Herpes simplex virus (HSV), mucocutaneous infection in HIV-infected patients (adolescents and adults); Herpes simplex virus (HSV), orolabial (cold sores) infection in immunocompetent patients; Herpes simplex virus (HSV), orolabial (cold sores) infection in HIV-infected patients (adolescents and adults); Herpes simplex virus reactivation (prevention in seropositive immunocompromised patients); Herpes zoster (shingles) in HIV-infected patients (adolescents and adults); Varicella (chickenpox) in HIV-infected patients (adolescent and adults); Varicella-zoster virus acute retinal necrosis (ARN) in HIV-infected patients (adolescent and adults); Varicella-zoster virus reactivation (prevention in HSCT recipients); VZV and HSV infection following solid organ transplantation; Disseminated primary eczema herpeticum; Empiric treatment of suspected encephalitis in immunocompromised patients with cancer; Herpes simplex-associated erythema multiforme; HSV gingivostomatitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7808290\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Acyclovir may be confused with famciclovir, ganciclovir, Retrovir, valacyclovir, valganciclovir</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zovirax may be confused with Doribax, Valtrex, Zithromax, Zostrix, Zyloprim, Zyvox</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7808308\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Central nervous system: Malaise (&le;12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (2% to 5%), vomiting (&le;3%), diarrhea (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parenteral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hives (2%), itching (2%), rash (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea/vomiting (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Liver function tests increased (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Inflammation at injection site or phlebitis (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: BUN increased (5% to 10%), creatinine increased (5% to 10%), acute renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>All forms:</b> &lt;1%, postmarketing, and/or case reports: Abdominal pain, aggression, agitation, anemia, anorexia, ataxia, coma, confusion, consciousness decreased, delirium, desquamation, disseminated intravascular coagulopathy (DIC), dizziness, dysarthria, encephalopathy, fatigue, fever, gastrointestinal distress, hallucinations, hematuria, hemolysis, hepatitis, hyperbilirubinemia, hypotension, insomnia, jaundice, leukocytoclastic vasculitis, leukocytosis, leukopenia, lymphadenopathy, mental depression, myalgia, neutrophilia, pain, psychosis, renal failure, renal pain, seizure, somnolence, sore throat, thrombocytopenia, thrombotic microangiopathy, thrombocytosis, visual disturbances</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7901079\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7908330\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Neurotoxicity (eg, tremor/myoclonus, confusion, agitation, lethargy, hallucination, impaired consciousness) has been reported; risk may be increased with higher doses and in patients with renal failure. Monitor patients for signs/symptoms of neurotoxicity; ensure appropriate dosage reductions in patients with renal impairment (Chowdhury 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Acyclovir IV is an irritant (depending on concentration); avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: Renal failure (sometimes fatal) has been reported. Dehydration, preexisting renal disease, and nephrotoxic drugs increase risk; ensure patient is adequately hydrated during oral or IV therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic microangiopathy: Has been reported in immunocompromised patients receiving acyclovir.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution; dosage adjustment recommended. Neurotoxicity may be more common in patients with renal impairment (Chowdhury 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Varicella: Appropriate use: For maximum benefit, treatment should begin within 24 hours of appearance of rash; oral route not recommended for routine use in otherwise healthy children with varicella but may be effective in patients at increased risk of moderate-to-severe infection (&gt;12 years of age, chronic cutaneous or pulmonary disorders, long-term salicylate therapy, corticosteroid therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Use IV preparation with caution in patients with underlying neurologic abnormalities, serious hepatic or electrolyte abnormalities, or substantial hypoxia. Encephalopathic changes characterized by lethargy, obtundation, confusion, hallucination, tremors, agitation, seizure, or coma have been observed in patients receiving IV acyclovir.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adequate hydration: Maintain adequate hydration during oral or IV therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298682\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP1A2 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7911154\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8628&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Acyclovir-Valacyclovir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Acyclovir-Valacyclovir may increase the serum concentration of Mycophenolate. Mycophenolate may increase the serum concentration of Acyclovir-Valacyclovir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Talimogene Laherparepvec: Antiherpetic Antivirals may diminish the therapeutic effect of Talimogene Laherparepvec. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Acyclovir-Valacyclovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Acyclovir-Valacyclovir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varicella Virus Vaccine: Acyclovir-Valacyclovir may diminish the therapeutic effect of Varicella Virus Vaccine.  Management: When possible, avoid use of acyclovir or valacyclovir within the 24 hours prior to administration of the varicella vaccine, and avoid use of these antiviral agents for 14 days after vaccination.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Acyclovir-Valacyclovir may enhance the CNS depressant effect of Zidovudine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zoster Vaccine (Live/Attenuated): Acyclovir-Valacyclovir may diminish the therapeutic effect of Zoster Vaccine (Live/Attenuated).  Management: When possible, discontinue antiviral agents with anti-zoster activity (i.e., acyclovir, valacyclovir, famciclovir) for at least 24 hours prior to and 14 days after receiving a live attenuated zoster vaccine.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7908326\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7908327\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects were not observed in animal reproduction studies. Acyclovir has been shown to cross the human placenta (Henderson 1992). Results from a pregnancy registry, established in 1984 and closed in 1999, did not find an increase in the number of birth defects with exposure to acyclovir when compared to those expected in the general population. However, due to the small size of the registry and lack of long-term data, the manufacturer recommends using during pregnancy with caution and only when clearly needed. Acyclovir is recommended for the treatment of genital herpes in pregnant women (CDC [Workowski 2015]). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7901078\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Acyclovir is excreted in breast milk. The manufacturer recommends that caution be exercised when administering acyclovir to nursing women. Limited data suggest exposure to the nursing infant of ~0.3 mg/kg/day following oral administration of acyclovir to the mother. Acyclovir may be used for the treatment of genital herpes in breastfeeding women (CDC [Workowski 2015]). Breast feeding mothers with herpetic lesions near or on the breast should avoid breast-feeding (Gartner 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7901189\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7908384\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Urinalysis, BUN, serum creatinine, urine output; liver enzymes, CBC; monitor for neurotoxicity and nephrotoxicity in pediatric patients when using high dose therapy; neutrophil count at least twice weekly in neonates receiving acyclovir 60 mg/kg/day IV. Monitor infusion site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7908334\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Acyclovir is converted to acyclovir monophosphate by virus-specific thymidine kinase then further converted to acyclovir triphosphate by other cellular enzymes. Acyclovir triphosphate inhibits DNA synthesis and viral replication by competing with deoxyguanosine triphosphate for viral DNA polymerase and being incorporated into viral DNA.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7808316\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Poorly absorbed; absorption improves with multiple small doses compared to one large daily dose (de Miranda 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Widely (eg, brain, kidney, lungs, liver, spleen, muscle, uterus, vagina, CSF) (de Miranda 1982; Laskin 1983); CSF acyclovir concentration is ~50% of plasma concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>dss </sub>(Blum 1982; Laskin 1983; Spector 1981):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neonates to 3 months of age: 28.8 L/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 2 years: 31.6 L/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 7 years: 42 L/1.73 m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 0.8 L/kg (63.6 L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 9% to 33%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Converted by viral enzymes to acyclovir monophosphate, and further converted to diphosphate then triphosphate (active form) by cellular enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: 10% to 20% with normal renal function (bioavailability decreases with increased dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: Neonates and Infants &le;3 months: 3.8 &plusmn; 1.19 hours; Infants &gt;3 months to Children &le;12 years: 2.36 &plusmn; 0.97 hours; Adults: ~2.5 hours (with normal renal function); 20 hours (ESRD) (Gorlitzsky 2017); Hemodialysis: ~5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (62% to 91% as unchanged drug and metabolite)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7912078\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Acyclovir Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $97.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Zovirax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $567.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Acyclovir Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (10 mL): $16.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Acyclovir Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $44.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Acyclovir Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL (473 mL): $445.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Zovirax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL (473 mL): $587.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Acyclovir Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $188.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (100): $366.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zovirax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $1,101.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (100): $2,141.32</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961951\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acic (AE, BH, EE, KW, LV, QA);</li>\n      <li>Aciclodan (DK);</li>\n      <li>Aciclor (VE);</li>\n      <li>Aciclosina (PT);</li>\n      <li>Acicvir (NZ);</li>\n      <li>Aciherpin (PH);</li>\n      <li>Acirax (LK, VN);</li>\n      <li>Acivir (BD, ET, LV);</li>\n      <li>Acivir Eye (IN);</li>\n      <li>Acivirex (GT, HN, NI, SV);</li>\n      <li>Aclovir (FI, TH, TW);</li>\n      <li>ACS (KR);</li>\n      <li>Activir (FR);</li>\n      <li>Acyclo-V (AU, BH);</li>\n      <li>Acyclovenir (IL);</li>\n      <li>Acylene (MY);</li>\n      <li>Acyrax (FI);</li>\n      <li>Acyvir (EC, IT, VN);</li>\n      <li>Aisike (CN);</li>\n      <li>Aisile (CN);</li>\n      <li>Alvoles (TH);</li>\n      <li>Antix (NO);</li>\n      <li>Avir (VE);</li>\n      <li>Avorax (HK);</li>\n      <li>Azost (PH);</li>\n      <li>Bangna (CN);</li>\n      <li>Bearax (SG);</li>\n      <li>Biraxin (PH);</li>\n      <li>Ciclevir (VN);</li>\n      <li>Cicloferon (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Cicloviral (CO);</li>\n      <li>Ciclox (PH);</li>\n      <li>Clinovir (ID, TH);</li>\n      <li>Clopes (ID);</li>\n      <li>Clovika (ID);</li>\n      <li>Clovir (KR, PH, PY, QA);</li>\n      <li>Clovirex (LK);</li>\n      <li>Covelay (PH);</li>\n      <li>Cusiviral (MY, QA, SG);</li>\n      <li>Cyclivex (ZA);</li>\n      <li>Cycloherp (HK);</li>\n      <li>Cyclostad (PH);</li>\n      <li>Cyclovax (TR);</li>\n      <li>Cyclovex (LB);</li>\n      <li>Cyclovir (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Cyllanvir (PH);</li>\n      <li>Deherp (TH, TW);</li>\n      <li>Docaciclo (BE);</li>\n      <li>Dravyr (MY, SG);</li>\n      <li>Duvimex (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ecuvir (EC);</li>\n      <li>Entir (SG, TH);</li>\n      <li>Erlvirax (SG);</li>\n      <li>Euroclovir (HK);</li>\n      <li>Eurovir (PY);</li>\n      <li>Expit (UY);</li>\n      <li>Gantai (CN);</li>\n      <li>Geavir (DK, SE);</li>\n      <li>Helvevir (CH);</li>\n      <li>Herax (ID);</li>\n      <li>Herpavir (JO);</li>\n      <li>Herperax (ZW);</li>\n      <li>Herpesin (CZ, SK);</li>\n      <li>Herpevex (MY);</li>\n      <li>Herpevir (FR);</li>\n      <li>Herpex (BH, ET, IN, PH, ZW);</li>\n      <li>Herpizyg (TH);</li>\n      <li>Heviran (PL);</li>\n      <li>Isavir (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Lermex (TH);</li>\n      <li>Licovir (ID);</li>\n      <li>Lisovyr (AR, CL);</li>\n      <li>Lovir (AE, AU, KW, NZ, PH, QA);</li>\n      <li>Lovire (ZA);</li>\n      <li>Marvir (TH);</li>\n      <li>Matrovir (ID);</li>\n      <li>Medovir (AE, BF, BG, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, OM, QA, SA, SC, SD, SG, SL, SN, SY, TN, TW, TZ, UA, UG, YE, ZM, ZW);</li>\n      <li>Mibeviru (VN);</li>\n      <li>Molavir (ID);</li>\n      <li>Norum (TH);</li>\n      <li>Noviral (QA);</li>\n      <li>Ozvir (AU);</li>\n      <li>Poviral (AR);</li>\n      <li>Qualiclovir (HK);</li>\n      <li>Ranvir (TH);</li>\n      <li>Reclovax (TH);</li>\n      <li>Remex (FR);</li>\n      <li>Skirax (TW);</li>\n      <li>Supraviran (JO, LB);</li>\n      <li>Vacrax (MY);</li>\n      <li>Vermis (TH);</li>\n      <li>Vialesel (ET);</li>\n      <li>Viralex-DS (PH);</li>\n      <li>Viramed (ZW);</li>\n      <li>Viratak (ZW);</li>\n      <li>Viratop (BE);</li>\n      <li>Virax (KR);</li>\n      <li>Virest (HK, SG);</li>\n      <li>Virex (CO);</li>\n      <li>Virherpes (ES);</li>\n      <li>Virless (LK, MY, SG, TW);</li>\n      <li>Viroclear (HK);</li>\n      <li>Virogon (TH);</li>\n      <li>Virolex (HU, RO);</li>\n      <li>Virolox (HR);</li>\n      <li>Viromed (TH);</li>\n      <li>Virpes (AE, JO);</li>\n      <li>Virucid (MT, TR, VN);</li>\n      <li>Virustat (JO);</li>\n      <li>Virzin (DE);</li>\n      <li>Vivir (KR);</li>\n      <li>Wariviron (LB, QA);</li>\n      <li>Xovir (BD);</li>\n      <li>Zevin (TH);</li>\n      <li>Ziverone (MX);</li>\n      <li>Zodiac (KR);</li>\n      <li>Zoral (HK, MY, SG);</li>\n      <li>Zorax (SG);</li>\n      <li>Zorexin (MY);</li>\n      <li>Zoter (ID);</li>\n      <li>Zovir (DK, IS);</li>\n      <li>Zovirax (AE, AR, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BO, BR, BS, CH, CI, CU, CY, CZ, EC, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HU, ID, IE, IL, IN, IQ, IR, IT, JM, JO, JP, KE, KR, KW, LB, LR, LU, LV, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PL, PR, PT, PY, QA, RU, SA, SC, SD, SE, SK, SL, SN, SY, TN, TR, TT, TW, TZ, UA, UG, UY, YE, ZA, ZM, ZW);</li>\n      <li>Zoylex (PE);</li>\n      <li>Zyvir (KE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7777108\"></a>Almond MK, Fan S, Dhillon S, Pollock AM, Raftery MJ. Avoiding acyclovir neurotoxicity in patients with chronic renal failure undergoing haemodialysis. <i>Nephron</i>. 1995;69(4):428-432.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/7777108/pubmed\" target=\"_blank\" id=\"7777108\">7777108</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds; <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds; <i>Red Book: 2009 Report of the Committee on Infectious Diseases</i>. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds; <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;The Use of Oral Acyclovir in Otherwise Healthy Children With Varicella,&rdquo; <i>Pediatrics</i>, 1993, 91(3):674-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/8382784/pubmed\" target=\"_blank\" id=\"8382784\">8382784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      Amir J, Harel L, Smetana Z, et al, &ldquo;Treatment of Herpes Simplex Gingivostomatitis With Aciclovir in Children: A Randomised, Double Blind Placebo Controlled Study,&rdquo; Br Med J 1997, 314(7097):1800-3. Available at http://www.bmj.com/content/314/7097/1800.full?sid=22b276f2-5ca8-4aae-8d10-2a4a299772bc9224082</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Balfour HH Jr. Antiviral drugs. <i>N Engl J Med</i>. 1999;340(16):1255-1268. doi: 10.1056/NEJM199904223401608.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/10210711/pubmed\" target=\"_blank\" id=\"10210711\">10210711</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7767151\"></a>Bergmann OJ, Ellermann-Eriksen S, Mogensen SC, Ellegaard J. Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial. <i>BMJ</i>. 1995;310(6988):1169-1172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/7767151/pubmed\" target=\"_blank\" id=\"7767151\">7767151</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blum MR, Liao SH, de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. <i>Am J Med</i>. 1982;73(1A):186-192.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/7048911/pubmed\" target=\"_blank\" id=\"7048911\">7048911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boeckh M, Kim HW, Flowers ME, et al, &ldquo;Long-Term Acyclovir for Prevention of Varicella Zoster Virus Disease After Allogeneic Hematopoietic Cell Transplantation- A Randomized Double-Blind Placebo-Controlled Study,&rdquo; <i>Blood</i>, 2006, 107(5):1800-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/16282339/pubmed\" target=\"_blank\" id=\"16282339\">16282339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 21st ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children. <i>MMWR Recomm Rep</i>. 2009;58(RR-11):1-166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/19730409/pubmed\" target=\"_blank\" id=\"19730409\">19730409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cernik C, Gallina K, and Brodell RT, &ldquo;The Treatment of Herpes Simplex Infections: An Evidence-Based Review,&rdquo; <i>Arch Int Med</i>, 2008, 168(11):1137-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/18541820/pubmed\" target=\"_blank\" id=\"18541820\">18541820</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24942005\"></a>Chowdhury MA, Derar N, Hasan S, Hinch B, Ratnam S, Assaly R. Acyclovir-induced neurotoxicity: a case report and review of literature. <i>Am J Ther</i>. 2016;23(3):e941-e943. doi: 10.1097/MJT.0000000000000093.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/24942005/pubmed\" target=\"_blank\" id=\"24942005\">24942005</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. <i>J Antimicrob Chemother.</i> 1983;12 (suppl B):29-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/6355048/pubmed\" target=\"_blank\" id=\"6355048\">6355048</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. July 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dunkle LM, Arvin AM, Whitley RJ, et al, &ldquo;A Controlled Trial of Acyclovir for Chickenpox in Normal Children,&rdquo; <i>N Engl J Med</i>, 1991, 325(22):1539-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/1944438/pubmed\" target=\"_blank\" id=\"1944438\">1944438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eck P, Silver SM, and Clark EC, &ldquo;Acute Renal Failure and Coma After a High Dose of Oral Acyclovir,&rdquo; <i>N Engl J Med</i>, 1991, 325(16):1178-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/1891032/pubmed\" target=\"_blank\" id=\"1891032\">1891032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eisen D, Essell J, Broun ER, et al, &ldquo;Clinical Utility of Oral Valacyclovir Compared With Oral Acyclovir for the Prevention of Herpes Simplex Virus Mucositis Following Autologous Bone Marrow Transplantation or Stem Cell Rescue Therapy,&rdquo; <i>Bone Marrow Transplant</i>, 2003, 31(1):51-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/12621507/pubmed\" target=\"_blank\" id=\"12621507\">12621507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Englund JA, Fletcher CV, and Balfour HH Jr, &ldquo;Acyclovir Therapy in Neonates,&rdquo; <i>J Pediatr</i>, 1991, 119(1 Pt 1):129-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/2066845/pubmed\" target=\"_blank\" id=\"2066845\">2066845</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26704611\"></a>Fife KH, Mugwanya K, Thomas KK, et al; Partners in Prevention HSV/HIV Transmission Study Team. Transient Increase in herpes simplex virus type 2 (HSV-2)-associated genital ulcers following initiation of antiretroviral therapy in HIV/HSV-2-coinfected individuals. <i>J Infect Dis</i>. 2016;213(10):1573-1578. doi: 10.1093/infdis/jiv765.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/26704611/pubmed\" target=\"_blank\" id=\"26704611\">26704611</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21205990\"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):427-431.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/21205990/pubmed\" target=\"_blank\" id=\"21205990\">21205990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gartner LM, Morton J, Lawrence RA, et al, &quot;Breastfeeding and the Use of Human Milk,&quot; <i>Pediatrics</i>, 2005, 115(2):496-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/15687461/pubmed\" target=\"_blank\" id=\"15687461\">15687461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28067468\"></a>Gorlitsky BR, Herion JT. Sticking to the script: A curious case of confusion in an ESRD patient [published online ahead of print January 9, 2017]. <i>Hemodial Int</i>. 2017. doi: 10.1111/hdi.12534.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/28067468/pubmed\" target=\"_blank\" id=\"28067468\">28067468</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gronseth GS, Paduga R; American Academy of Neurology. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2012;79(22):2209-2213. doi: 10.1212/WNL.0b013e318275978c.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/23136264/pubmed\" target=\"_blank\" id=\"23136264\">23136264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15889353\"></a>Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2005;40(11):1559-1585.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/15889353/pubmed\" target=\"_blank\" id=\"15889353\">15889353</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Henderson GI, Hu ZQ, Johnson RF, et al, &quot;Acyclovir Transport by the Human Placenta,&quot; <i>J Lab Clin Med</i>, 1992, 120(6):885-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/1453110/pubmed\" target=\"_blank\" id=\"1453110\">1453110</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hyland PL, Coulter WA, Abu-Ruman I, et al. Asymptomatic shedding of HSV-1 in patients undergoing oral surgical procedures and attending for noninvasive treatment. <i>Oral Dis.</i> 2007;13(4):414-418.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/17577329/pubmed\" target=\"_blank\" id=\"17577329\">17577329</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kimberlin DW, Baley J; Committee on Infectious Diseases; Committee on Fetus and Newborn. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. <i>Pediatrics</i>. 2013;131(2):e635-e646. doi: 10.1542/peds.2012-3216.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/23359576/pubmed\" target=\"_blank\" id=\"23359576\">23359576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kimberlin DW, Whitley RJ, Wan W, et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Oral acyclovir suppression and neurodevelopment after neonatal herpes. <i>N Engl J Med</i>. 2011;365(14):1284-1292. doi: 10.1056/NEJMoa1003509.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/21991950/pubmed\" target=\"_blank\" id=\"21991950\">21991950</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laskin OL. Clinical pharmacokinetics of acyclovir. <i>Clin Pharmacokinet</i>. 1983;8(3):187-201.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/6342900/pubmed\" target=\"_blank\" id=\"6342900\">6342900</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leflore S, Anderson PL, and Fletcher CV. &ldquo;A Risk-Benefit Evaluation of Aciclovir for the Treatment and Prophylaxis of Herpes Simplex Virus Infections,&rdquo; <i>Drug Safety</i>, 2000, 23(2):131-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/10945375/pubmed\" target=\"_blank\" id=\"10945375\">10945375</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Novelli VM, Marshall WC, Yeo J, et al, &ldquo;High-Dose Oral Acyclovir for Children at Risk of Disseminated Herpesvirus Infections,&rdquo; <i>J Infect Dis</i>, 1985, 151(2):372.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/2981940/pubmed\" target=\"_blank\" id=\"2981940\">2981940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raborn GW, Martel AY, Grace MG, et al, &ldquo;Oral Acyclovir in Prevention of Herpes Labialis. A Randomized, Double-Blind, Multi-Centered Clinical Trial,&rdquo; <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i>, 1998, 85(1):55-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/9474615/pubmed\" target=\"_blank\" id=\"9474615\">9474615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rahimi H, Mara T, Costella J, Speechley M, Bohay R. Effectiveness of antiviral agents for the prevention of recurrent herpes labialis: a systemic review and meta-analysis. <i>Oral Surg Oral Med Oral Pathol Oral Radiol.</i> 2012;113:618-627.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/22668620/pubmed\" target=\"_blank\" id=\"22668620\">22668620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rao S, Abzug MJ, Carosone-Link P, et al. Intravenous acyclovir and renal dysfunction in children: a matched case control study. <i>J Pediatr</i>. 2016;166(6):1462-14628.e1-4. doi: 10.1016/j.jpeds.2015.01.023.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/25708691/pubmed\" target=\"_blank\" id=\"25708691\">25708691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rayani SA, Nimmo CJ, Frighetto L, et al, &ldquo;Implementation and Evaluation of a Standardized Herpes Simplex Virus Prophylaxis Protocol on a Leukemia/Bone Marrow Transplant Unit,&rdquo; <i>Ann Pharmacother</i>, 1994, 28(7-8):852-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/7949499/pubmed\" target=\"_blank\" id=\"7949499\">7949499</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8380540\"></a>Rooney JF, Straus SE, Mannix ML, et al. Oral acyclovir to suppress frequently recurrent herpes labialis. a double-blind, placebo-controlled trial. <i>Ann Intern Med.</i> 1993;118(4):268-272.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/8380540/pubmed\" target=\"_blank\" id=\"8380540\">8380540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spector SA, Connor JD, Hintz M, et al. Single-dose pharmacokinetics of acyclovir. <i>Antimicrob Agents Chemother.</i> 1981;19(4):608-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/7247383/pubmed\" target=\"_blank\" id=\"7247383\">7247383</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spruance SL, Hamill ML, Hoge WS, et al, &ldquo;Acyclovir Prevents Reactivation of Herpes Simplex Labialis in Skiers,&rdquo; <i>JAMA</i>, 1988, 260(11):1597-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/3411740/pubmed\" target=\"_blank\" id=\"3411740\">3411740</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2153735\"></a>Spruance SL, Stewart JCB, Rowe NH, et al, &ldquo;Treatment of Recurrent Herpes Simplex Labialis With Oral Acyclovir,&rdquo; <i>J Infect Dis</i>, 1990, 161(2):185-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/2153735/pubmed\" target=\"_blank\" id=\"2153735\">2153735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8893152\"></a>Stathoulopoulou F, Almond MK, Dhillon S, Raftery MJ. Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. <i>Nephron</i>. 1996;74(2):337-341.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/8893152/pubmed\" target=\"_blank\" id=\"8893152\">8893152</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tiffany KF, Benjamin DK Jr, Palasanthiran P, et al. Improved neurodevelopmental outcomes following long-term high-dose oral acyclovir therapy in infants with central nervous system and disseminated herpes simplex disease. <i>J Perinatol</i>. 2005;25(3):156-161.doi: 10.1038/sj.jp.7211247.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/15605069/pubmed\" target=\"_blank\" id=\"15605069\">15605069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19747629\"></a>Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction appears in <i>Biol Blood Marrow Transplant</i>. 2010;16(2):294]. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Glaser CA, Bloch KC, et al; Infectious Diseases Society of America. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2008;47(3):303-327. doi: 10.1086/589747.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/18582201/pubmed\" target=\"_blank\" id=\"18582201\">18582201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26824940\"></a>Turner RB, Cumpston A, Sweet M, et al. Prospective, controlled study of acyclovir pharmacokinetics in obese patients. <i>Antimicrob Agents Chemother</i>. 2016;60(3):1830-3. doi:10.1128/AAC.02010-15<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/26824940/pubmed\" target=\"_blank\" id=\"26824940\">26824940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27067742\"></a>Wong A, Pickering AJ, Potoski BA. Dosing practices of intravenous acyclovir for herpes encephalitis in obesity: results of a pharmacist survey. <i>J Pharm Pract</i>. 2017;30(3):324-328. doi: 10.1177/0897190016642689<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/27067742/pubmed\" target=\"_blank\" id=\"27067742\">27067742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wood MJ, Johnson RW, McKendrick MW, et al, &ldquo;A Randomized Trial of Acyclovir for 7 Days or 21 Days With and Without Prednisolone for Treatment of Acute Herpes Zoster,&rdquo; <i>N Engl J Med</i>, 1994, 330(13):896-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/8114860/pubmed\" target=\"_blank\" id=\"8114860\">8114860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acyclovir-systemic-drug-information/abstract-text/26042815 /pubmed\" target=\"_blank\" id=\"26042815 \">26042815 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8628 Version 272.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7808291\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F7808292\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F7912017\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F7901185\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F7901184\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F7901186\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F7901187\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671282\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20330460\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F7901193\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F7908323\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7808318\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F7908324\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475020\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7808290\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7808308\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F7901079\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7908330\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298682\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F7911154\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F7908326\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7908327\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F7901078\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F7901189\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F7908384\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7908334\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F7808316\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F7912078\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961951\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8628|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=acyclovir-systemic-patient-drug-information\" class=\"drug drug_patient\">Acyclovir (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=acyclovir-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Acyclovir (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}